(NASDAQ: SGMO) Sangamo Therapeutics's forecast annual revenue growth rate of 48.3% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 105.94%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.68%.
Sangamo Therapeutics's revenue in 2025 is $32,875,000.On average, 8 Wall Street analysts forecast SGMO's revenue for 2025 to be $24,986,734,775, with the lowest SGMO revenue forecast at $11,442,831,593, and the highest SGMO revenue forecast at $44,060,588,390. On average, 8 Wall Street analysts forecast SGMO's revenue for 2026 to be $20,553,419,883, with the lowest SGMO revenue forecast at $2,835,975,553, and the highest SGMO revenue forecast at $41,691,667,187.
In 2027, SGMO is forecast to generate $40,638,439,437 in revenue, with the lowest revenue forecast at $6,595,291,984 and the highest revenue forecast at $92,428,306,239.